PicoCELA Inc. (NASDAQ:PCLA) Short Interest Up 29,900.8% in December

PicoCELA Inc. (NASDAQ:PCLA) was the target of a large increase in short interest in December. As of December 31st, there was short interest totaling 3,625,291 shares, an increase of 29,900.8% from the December 15th total of 12,084 shares. Currently, 13.3% of the company’s stock are short sold. Based on an average daily volume of 110,555,509 shares, the days-to-cover ratio is presently 0.0 days. Based on an average daily volume of 110,555,509 shares, the days-to-cover ratio is presently 0.0 days. Currently, 13.3% of the company’s stock are short sold.

Institutional Trading of PicoCELA

An institutional investor recently bought a new position in PicoCELA stock. XTX Topco Ltd bought a new stake in PicoCELA Inc. (NASDAQ:PCLA) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned 0.16% of PicoCELA as of its most recent filing with the Securities & Exchange Commission.

PicoCELA Stock Down 6.5%

Shares of NASDAQ PCLA opened at $0.25 on Tuesday. The firm’s 50-day moving average price is $0.29 and its 200-day moving average price is $0.57. PicoCELA has a 52-week low of $0.12 and a 52-week high of $9.80.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of PicoCELA in a report on Tuesday, October 14th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

PicoCELA Company Profile

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.